{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-22-000026","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2022-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.241320+00:00","generated_at":"2026-06-26T00:52:02.192915+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"10x Genomics Q1 revenue $114.5M (+8% YoY); net loss widens to $42.4M; FY22 guidance maintained","bullets":["Revenue $114.5M, up 8% YoY from $105.8M; gross margin fell to 78% from 84%.","Net loss $42.4M vs $11.6M in Q1 2021; operating loss $41.7M including $26.0M stock-based comp.","Operating expenses rose 32% to $130.8M driven by higher personnel, R&D, and infrastructure costs.","Cash and marketable securities $539.3M as of March 31, 2022.","Full-year 2022 revenue guidance maintained at $600M-$630M, implying 22-28% growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-22-000026","json":"https://secwatch.observer/filing/0001770787-22-000026.json","markdown":"https://secwatch.observer/filing/0001770787-22-000026.md","text":"https://secwatch.observer/filing/0001770787-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000026/0001770787-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078722000026/txg-20220504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T00:52:02.192915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}